



HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT 2024



PHRAMONGKUTKLAO HOSPITAL

ARMY MEDICAL DEPARTMENT
MINISTRY OF DEFENCE
THAILAND

PHRAMONGKUTKLAO HOSPITAL EXCELLENT CENTER OF CANCER CARE

2024



Title

Phramongkutklao Hospital Cancer Registry
Report 2024

Editorial Board

Naiyarat Prasongsook, M.D.

Chairman of cancer Registry Committee,
Chairman Excellent Center of Cancer Care.

Kritsada Srithanaphakarangkul, M.D.

Chairman of Cancer of the Data
Information committee

Published by

Clinical Epidemiology Unit and Oncology
Department,

Phramongkutklao Hospital

315 Chalermprakiet Building, Ratchawithi Road,
Ratchathewi District, Thung Phaya Thai
Subdistrict. Bangkok 10400

Tel. : 02763 3925, 02763 3047

Published

2025

Edition

Seventeenth

Physical

73 pages



EXCELLENT CENTER OF CANCER CARE

HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2024

Phramongkutklo Hospital
Royal Thai Army Medical Department
Ministry of Defence
Bangkok, Thailand

Edited By
Y. Tanapat and K. Srithanaphakarangkul

Edition : December 2024

MESSAGE FROM DIRECTOR OF PHRAMONGKUTKLAO HOSPITAL



The Phramongkutklo Hospital is proud to present the Cancer Registry Report 2024. The report collects information on all new cancer cases. Data collected include the clinical characteristics of the cancer (site, histology, behavior, grade, extent of disease) and treatment details on the cancer patient. The registry has a comprehensive quality assurance program in place to ensure that the data are complete, accurate and timely.

I would like to thank all our collaborators for their dedication in providing data presented in this volume. I would like to express my gratitude to the devoted staffs of cancer registry in all cancer units for the immense amount of work that has been done in preparation of the statistics and graphics for this volume.

A handwritten signature in black ink that reads "S. Sathaporn".

Sukchai Sathaporn Maj. Gen.
Director General of Phramongkutklo Hospital




INTRODUCTION

The Phramongkutklao Hospital Cancer Registry Report 2024 is a hospital-based cancer registry of new cancer patients initially diagnosed or initially treated at Phramongkutklao Cancer Center from January 1, 2024, to December 31, 2024. All new cancer patients registered during the mentioned period were treated at the various Cancer Units under The Excellent center of Cancer Care, Phramongkutklao Hospital. Patients were either primarily diagnosed or referred from army hospitals (under supervision of the Royal Thai Army Medical Department) as well as public and private hospitals. The objective of this is to report new cancer patients regarding method of diagnosis, pathological types, staging, behavior, grading, extension, and primary treatment modalities. Phramongkutklao Hospital has initiated a hospital cancer registry system based on the existing hospital data management system since 2009. This system has enabled physicians and nurses taking care of cancer patients to update patient information on the cancer registry at Cancer Units on a real-time basis. Thus, information obtained can be corrected and updated by persons in charge of patient care at the time of the patient's hospital visit. This process should contribute to the validity of information in the Cancer Registry.

This Cancer Registry Report would not be possible without the dedicated input of data from the staff of the Cancer Clinics and the Cancer Units from different departments at Phramongkutklao Cancer Center.



Assist. Prof. Naiyarat Prasongsook, M.D., M.S., COL.
Chairman Cancer Registry Committee
Phramongkutklao Cancer Center



EXCELLENT CENTER OF CANCER CARE PHRAMONGKUTKLAO HOSPITAL

1.	Maj.Gen. Sukchai	Satthaporn	Consultant
2.	Col. Pariyanan	Jaruchinda	Consultant
3.	Col. Rachata	Lumkul	Consultant
4.	Col. Kasan	Seetalarom	Consultant
5.	Col. Naiyarat	Prasongsook	Chairman of Administor Committee
6.	Col. Chinakrit	BoonyaUssadorn	Member
7.	Col. Satit	Siriboonrid	Member
8.	Col. Sirinthip	Songwutwichai	Member
9.	Col. Chanchai	Traivaree	Member
10.	Col. Phutsapong	Srisawat	Member
11.	Lt.Col. Sithapan	Munjupong	Member
12.	Col. Kristsanamon	Rittiluechai	Member
13.	Lt.Col. Chonlada	Laoruagroj	Member
14.	Col. Vana	Sangsasri	Member
15.	Lt.Col. Jarey	Ketsirichai	Member
16.	Lt.Col. Siriwimon	Saichaemchan	Member
17.	Lt.Col. Watcharaporn	bourchom	Member
18.	Lt.Col. Kanya	Ketkong	Member
19.	Lt.Col. Nattapoang	Binsri	Member
20.	Lt.Col. Chalinee	Monseereusorn	Member
21.	Lt.Col. Usa	Rittitada	Member
22.	Lt.Col. Supicha	Wongphun	Member



EXCELLENT CENTER OF CANCER CARE PHRAMONGKUTKLAO HOSPITAL

23.	Lt.Col. Kannadit	Prayongratana	Member
24.	Maj. Suvicha	Khampunnip	Member
25.	Maj. Sujitra	Shoolerd	Member
26.	Maj. Weerawan	Kaesai	Member
27.	Maj. Piyanuch	Srisuk	Member
28.	Maj. Nongnut	Seedapalee	Member
29.	Lt.Col. Rapeeporn	Kanchanapachana	Member
30.	Maj. Chetsuda	Khwanakorn	Member
31.	Capt. Sutipat	Pairojboriboon	Member
32.	Lt. Chatchanin	Ajalanond	Member
33.	Dr. Panjawit	Wuttipanich	Member
34.	Maj. wanvipa	Malaithong	Member
35.	Capt. Supittha	Tongpit	Member
36.	Maj. Phapasi	Punphasoed	Member
37.	Col. Jariya	Ketkao	Member
38.	Col. Waniknan	Hatsadin	Member
39.	Capt. Patcharaporn	liamsuwan	Member
40.	Capt. Atcharaporn	Sittichai	Member

CANCER REGISTRY STAFF

- | | | | |
|----|-----------------|----------|--------------------|
| 1. | Miss Rungthip | Boonyai | B.Com. (Computer) |
| 2. | Miss Chawanphat | Udomphon | B.Sc. (Statistics) |



TABLE OF CONTENTS

Title		
List of tables:		Page
Table 1	Distribution of new cancer patients by gender: 2024	1
Table 2	Number of all new patients: 2013-2024	2
Table 3	Ten leading primary sites of new cancer patients by gender: 2024	3
Table 4	Ten leading primary sites of new cancer patients in male: 2024	4
Table 5	Ten leading primary sites of new cancer patients in female: 2024	5
Table 6	Distribution of new cancer patients by age group and gender: 2024	6
Table 7	Distribution of new cancer patients by stage and gender: 2024	7
Table 8	Distribution of new cancer patients by grade and gender : 2024	8
Table 9	Distribution of new cancer patients by extension and gender: 2024	9
Table 10	Distribution of new cancer patients by method and gender: 2024	10
Table 11	Distribution of new cancer patients by treatment modalities and gender: 2024	11
Table 11	Distribution of new cancer patients by treatment modalities and gender: 2024	12
Table 12	Distribution of new cancer patients by treatment unit and gender: 2024	13
Table 13	Distribution of new cancer patients by status 2024	14
Table 14	Distribution of new cancer patients by follow up status and gender 2024	14
Table 15	Distribution of new military personnel cancer patients by age group and gender: 2024	15
Table 16	Distribution of new cancer patients by rank and gender: 2024	16
Table 17	Distribution of new childhood cancer patients (age 0-19) by age group and gender: 2024	17
Table 18	Distribution of new childhood cancer patients (age 0-19) by primary sites: 2024	17
Table 19	Distribution of new childhood cancer patients (age 0-19) by treatment modalities and gender: 2024	18
Table 20	Distribution of new childhood cancer patients (age 0-19) by method and gender: 2024	18
Table 21	Distribution of new childhood cancer patients (age 0-19) by type of extension and gender: 2024	19
Table 22	Distribution of new childhood cancer patients (age 0-19) by follow up and gender: 2024	19
Table 23	Number of new cancer patient stage and gender: 2024	20

TABLE OF CONTENTS

Title		Page
List of tables:		
Description of the leading site of cancers ordinal 1-3		
1. Breast cancer		
Table 24	Trend of breast cancer in Phramongkutklao hospital: 2013-2024	26
Table 25	Distribution of new breast cancer patients by age group and gender: 2024	27
Table 26	Distribution of new breast cancer patients by stage and gender: 2024	28
Table 27	Distribution of new breast cancer patients by method and gender: 2024	29
Table 28	Distribution of new breast cancer patients by extension and gender: 2024	29
Table 29	Distribution of new breast cancer patients by treatment modalities and gender: 2024	30
Table 30	Distribution of new breast cancer patients by follow up status and gender: 2024	31
2. Colon and rectum cancer		
Table 31	Trend of colon and rectum cancer in Phramongkutklao hospital: 2013-2024	32
Table 32	Distribution of new colon and rectum cancer patients by age group and gender: 2024	33
Table 33	Distribution of new colon and rectum cancer patients by stage and gender: 2024	34
Table 34	Distribution of new colon and rectum cancer patients by method and gender: 2024	35
Table 35	Distribution of new colon and rectum cancer patients by extension and gender: 2024	35
Table 36	Distribution of new colon and rectum cancer patients by treatment modalities and gender: 2024	36
Table 37	Distribution of new colon and rectum cancer patients by follow up status and gender: 2024	36
3. Bronchus, and lung cancer		
Table 38	Trend of bronchus, and lung cancer in Phramongkutklao hospital: 2013-2024	37
Table 39	Distribution of new bronchus and lung cancer patients by age group and gender: 2024	38
Table 40	Distribution of new bronchus and lung cancer patients by stage and gender: 2024	39
Table 41	Distribution of new bronchus and lung cancer patients by method and gender: 2024	40
Table 42	Distribution of new bronchus and lung cancer patients by extension and gender: 2024	40
Table 43	Distribution of new bronchus and lung cancer patients by treatment modalities and gender: 2024	41
Table 44	Distribution of new bronchus, and lung cancer patients by follow up status and gender: 2024	41

TABLE OF CONTENTS

Title		
List of tables:		Page
Description of the leading site of cancers ordinal 4-6		
4. Thyroid cancer		
Table 45	Distribution of new Thyroid cancer patients by age group and gender : 2024	42
Table 46	Distribution of new Thyroid cancer patients by stage and gender : 2024	43
Table 47	Distribution of new Thyroid cancer patients by method and gender : 2024	44
Table 48	Distribution of new Thyroid cancer patients by extension and gender : 2024	44
Table 49	Distribution of new Thyroid cancer patients by treatment modalities and gender : 2024	45
Table 50	Distribution of new Thyroid cancer patients by follow up status and gender : 2024	45
5. Prostate gland cancer		
Table 51	Distribution of new Prostate gland cancer patients by age group and gender: 2024	46
Table 52	Distribution of new Prostate gland cancer patients by stage and gender: 2024	47
Table 53	Distribution of new Prostate gland cancer patients by method and gender: 2024	48
Table 54	Distribution of new Prostate gland cancer patients by extension and gender: 2024	48
Table 55	Distribution of new Prostate gland cancer patients by treatment modalities and gender: 2024	49
Table 56	Distribution of new Prostate gland cancer patients by follow up status and gender: 2024	49
6. Liver and intrahepatic bile ducts cancer		
Table 57	Distribution of new Liver and intrahepatic bile ducts cancer patients by age group and gender: 2024	50
Table 58	Distribution of new Liver and intrahepatic bile ducts cancer patients by stage and gender: 2024	51
Table 59	Distribution of new Liver and intrahepatic bile ducts cancer patients by method and gender: 2024	52
Table 60	Distribution of new Liver and intrahepatic bile ducts cancer patients by extension and gender: 2024	52
Table 61	Distribution of new Liver and intrahepatic bile ducts cancer patients by treatment modalities and gender: 2024	53
Table 62	Distribution of new Liver and intrahepatic bile ducts cancer patients by follow up status and gender: 2024	53




TABLE OF CONTENTS

Title		
List of tables:		Page
Number of cases by age-group in sex		
Table 63	Distribution of new cancer in male by age - group: 2024	54
Table 64	Distribution of new cancer in female by age - group: 2024	55
Distribution of new cancer in by morphology and site: 2024		
Table 65	Distribution of new cancer patients by morphology and site: 2024	56
Distribution of new cancer patients: 2020-2024		
Table 66	Number of new cancer patients: 2019-2023	69
Table 67	Distribution of new cancer patients by follow up and gender: 2020-2024	69
Table 68	The leading primary sites of new cancer by gender: 2020-2024	70
Table 69	The leading primary sites of new cancer by follow up and gender: 2020-2024	70
Table 70	The 60 months survival time (median) top 6 by gender in 2020 - 2024	71



FIGURE OF CONTENTS

Title		
List of figures:		Page
Figure 1	All new cancer cases in Phramongkutklao hospital :2013-2024	1
Figure 2	Trend of number of all new cancer patients by gender :2013-2024	2
Figure 3	Ten leading primary sites of new cancer patients by gender: 2024	3
Figure 4	Ten leading primary sites of new cancer patients in male: 2024	4
Figure 5	Ten leading primary sites of new cancer patients in female: 2024	5
Figure 6	Distribution of new cancer patients by age group and gender: 2024	6
Figure 7	Distribution of new cancer patients by stage and gender: 2024	7
Figure 8	Distribution of new cancer patients by grade and gender: 2024	8
Figure 9	Distribution of new cancer patients by extension and gender: 2024	9
Figure 10	Distribution of new cancer patients by method and gender: 2024	10
Figure 11	Distribution of new cancer patients by treatment unit and gender: 2024	13
Figure 12	Distribution of new cancer patients by follow up status: 2024	14
Figure 13	Distribution of new military personnel cancer patients by age group and gender: 2024	15
Figure 14	Distribution of new cancer patients by rank and gender: 2024	16



FIGURE OF CONTENTS

Title		
List of figures:		Page
Description of the leading site of cancers ordinal 1-3		
1. Breast cancer		
Figure 15	Distribution of new breast cancer patients by age group and gender: 2024	27
Figure 16	Distribution of new breast cancer patients by stage and gender: 2024	28
Figure 17	Distribution of new breast cancer patients by extension and gender: 2024	29
2. Colon and rectum cancer		
Figure 18	Distribution of new colon and rectum cancer patients by age group and gender: 2024	33
Figure 19	Distribution of new colon and rectum cancer patients by stage and gender: 2024	34
Figure 20	Distribution of new colon and rectum cancer patients by extension and gender: 2024	35
3. Bronchus, and lung cancer		
Figure 21	Distribution of new bronchus and lung cancer patients by age group and gender: 2024	38
Figure 22	Distribution of new bronchus and lung cancer patients by stage and gender: 2024	39
Figure 23	Distribution of new bronchus and lung cancer patients by extension and gender: 2024	40
4. Thyroid gland		
Figure 24	Distribution of new Thyroid gland cancer patients by age group and gender: 2024	42
Figure 25	Distribution of new Thyroid gland cancer patients by stage and gender: 2024	43
Figure 26	Distribution of new Thyroid gland cancer patients by extension and gender: 2024	44
5. Prostate gland		
Figure 27	Distribution of new Prostate gland cancer patients by age group and gender: 2024	46
Figure 28	Distribution of new Prostate gland cancer patients by stage and gender: 2024	47
Figure 29	Distribution of new Prostate gland cancer patients by extension and gender: 2024	48
6. Liver and intrahepatic bile ducts cancer		
Figure 30	Distribution of new Liver and intrahepatic bile ducts cancer patients by age group and gender: 2024	50
Figure 31	Distribution of new Liver and intrahepatic bile ducts cancer patients by stage and gender: 2024	51
Figure 32	Distribution of new Liver and intrahepatic bile ducts cancer patients by extension and gender: 2024	52

FIGURE OF CONTENTS

Title		
List of tables:		Page
Number of cases by age-group in sex		
Distribution of the 60-month survival rate of cancers in : 2020 – 2024		
Figure 32	The 60 months survival rate (top 6) in 2020 – 2024	71
Figure 33	The 60 months survival rate (top 6) by male in 2020 – 2024	72
Figure 34	The 60 months survival rate (top 6) by Female in 2020 – 2024	73




2024 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



Type of patients	Number of cases
Total new hospital patients	44,300 (100.00%)
Total new cancer patients	1,924 (4.34%)
Gender distribution of cancer	
• Male	944 (2.13%)
• Female	980 (2.21%)

FIGURE 1: ALL NEW CANCER CASE IN PHRAMONGKUTKLOA HOSPITAL: 2013 – 2024






HOSPITAL-BASED CANCER REGISTRY **2024**

ANNUAL REPORT

TABLE 2 NUMBER OF ALL NEW PATIENTS : 2013 – 2024

Years	New patient	New cancer case	Case	Male		Female	
	Number	Number	Percent	Number	Percent	Number	Percent
2556 (2013)	66,151	1,801	2.72	897	1.36	904	1.37
2557 (2014)	68,306	1,856	2.72	947	1.39	909	1.33
2558 (2015)	55,484	1,536	2.77	801	1.44	735	1.32
2559 (2016)	59,191	1,771	2.99	881	1.49	890	1.50
2560 (2017)	58,320	1,539	2.64	779	1.34	760	1.30
2561 (2018)	55,771	1,666	2.99	886	1.59	780	1.40
2562 (2019)	57,049	1,720	3.01	885	1.55	835	1.46
2563 (2020)	42,412	1,608	3.79	800	1.89	808	1.91
2564 (2021)	46,210	1,526	3.30	771	1.67	755	1.63
2565 (2022)	47,768	1,702	3.56	822	1.72	880	1.84
2566 (2023)	41,671	1,825	4.38	912	2.19	913	2.19
2567 (2024)	44,300	1,924	4.34	944	2.13	980	2.21

FIGURE 2: TREND OF NUMBER OF ALL NEW PATIENTS BY GENDER: 2013 – 2024




2024 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



Ordinal	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
1	Breast	1	0.1	230	23.5	231	12.0
2	Colon & Rectum	126	13.3	104	10.6	230	12.0
3	bronchus & lung	120	12.7	100	10.2	220	11.4
4	Thyroid gland	31	3.3	113	11.5	144	7.5
5	Prostate gland	143	15.1	0	0.0	143	7.4
6	Liver & intrahepatic bile ducts	89	9.4	29	3.0	118	6.1
7	Lip & Oral cavity	70	7.4	26	2.7	96	5.0
8	Digestive organ	59	6.3	36	3.7	95	4.9
9	Non-Hodgkin's lymphoma	64	6.8	29	3.0	93	4.8
10	leukemia	41	4.3	39	4.0	80	4.2
	Others	200	21.2	274	28.0	474	24.6
	Total	944	100.0	980	100.0	1924	100.0

FIGURE 3: TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS BY GENDER: 2024





HOSPITAL-BASED CANCER REGISTRY **2024** ANNUAL REPORT

TABLE 4 TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN MALE : 2024			
Ordinal	Primary site	Number	Percent
1	Prostate gland	143	15.15
2	Colon & Rectum	126	13.35
3	bronchus & lung	120	12.71
4	Liver & intrahepatic bile ducts	89	9.43
5	Lip & Oral cavity	70	7.42
6	Non-Hodgkin's lymphoma	64	6.78
7	Digestive organ	59	6.25
8	leukemia	41	4.34
9	Bladder	36	3.81
10	Pancreas	32	3.39
Others		164	17.37
Total		944	100.00

FIGURE 4: TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN MALE: 2024







TABLE 5 TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN FEMALE : 2024			
Ordinal	Primary site	Number	Percent
1	Breast	230	23.47
2	Thyroid gland	113	11.53
3	Colon & Rectum	104	10.61
4	bronchus & lung	100	10.20
5	Uterus	64	6.53
6	Cervix	62	6.33
7	Ovary	41	4.18
8	leukemia	39	3.98
9	Digestive organ	36	3.67
10	Non-Hodgkin's lymphoma	29	2.96
	Liver & intrahepatic bile ducts	29	2.96
Others		133	13.57
Total		980	100.00

FIGURE 5: TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN FEMALE: 2024






HOSPITAL-BASED CANCER REGISTRY **2024**

ANNUAL REPORT

Age group	DISTRIBUTION OF NEW CANCER PATIENTS BY AGE GROUP AND GENDER : 2024					
	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
0-4	5	0.5	3	0.3	8	0.4
5-9	3	0.3	2	0.2	5	0.3
10-14	6	0.6	1	0.1	7	0.4
15-19	1	0.1	2	0.2	3	0.2
20-24	10	1.1	7	0.7	17	0.9
25-29	11	1.2	27	2.8	38	2.0
30-34	19	2.0	35	3.6	54	2.8
35-39	17	1.8	52	5.3	69	3.6
40-44	29	3.1	69	7.0	98	5.1
45-49	51	5.4	100	10.2	151	7.8
50-54	70	7.4	107	10.9	177	9.2
55-59	91	9.6	116	11.8	207	10.8
60-64	143	15.1	121	12.3	264	13.7
65-69	156	16.5	106	10.8	262	13.6
70-74	124	13.1	73	7.4	197	10.2
75-79	99	10.5	68	6.9	167	8.7
80-84	57	6.0	47	4.8	104	5.4
85+	52	5.5	44	4.5	96	5.0
Total	944	100.0	980	100.0	1924	100.0

Majority of cases

FIGURE 6: DISTRIBUTION OF NEW CANCER PATIENTS BY AGE GROUP AND GENDER: 2024



2024 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



TABLE 7 DISTRIBUTION OF NEW CANCER PATIENTS BY STAGE AND GENDER : 2024						
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	186	19.7	299	30.5	485	25.2
Stage II	198	21.0	199	20.3	397	20.6
Stage III	210	22.2	200	20.4	410	21.3
Stage IV	313	33.2	251	25.6	564	29.3
No stage	31	3.3	20	2.0	51	2.7
Unknown	6	0.6	11	1.1	17	0.9
Total	944	100.0	980	100.0	1924	100.0

*No stage: manual system including leukemia and brain

FIGURE 7: DISTRIBUTION OF NEW CANCER PATIENTS BY STAGE AND GENDER: 2024






TABLE 8

DISTRIBUTION OF NEW CANCER PATIENTS BY GRADE AND GENDER : 2024

Grade	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Well differentiated	117	12.4	142	14.5	259	13.5
Moderately differentiated	176	18.6	237	24.2	413	21.5
Poorly differentiated	223	23.6	226	23.1	449	23.3
Undifferentiated	67	7.1	5	0.5	72	3.7
T – Cell	35	3.7	36	3.7	71	3.7
B – Cell	74	7.8	34	3.5	108	5.6
Differentiated not Determined	252	26.7	300	30.6	552	28.7
Total	944	100.0	980	100.0	1924	100.0

FIGURE 8: DISTRIBUTION OF NEW CANCER PATIENTS BY GRADE AND GENDER: 2024







TABLE 9 DISTRIBUTION OF NEW CANCER PATIENTS BY EXTENSION AND GENDER : 2024						
Extend	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	595	63.0	632	64.5	1227	63.8
Regional lymph nodes	113	12.0	131	13.4	244	12.7
Distant metastasis	236	25.0	217	22.1	453	23.5
Total	944	100.0	980	100.0	1924	100.0

FIGURE 9: DISTRIBUTION OF NEW CANCER PATIENTS BY EXTENSION AND GENDER: 2024





HOSPITAL-BASED CANCER REGISTRY 2024 ANNUAL REPORT

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	7	0.7	12	1.2	19	1.0
Histopathology or Cytology	777	82.3	885	90.3	1662	86.4
Endoscopy	9	1.0	7	0.7	16	0.8
Bone marrow examination	108	11.4	68	6.9	176	9.1
Tumor marker	43	4.6	8	0.8	51	2.7
Total	944	100.0	980	100.0	1924	100.0

FIGURE 10: DISTRIBUTION OF NEW CANCER PATIENTS BY METHOD AND GENDER: 2024






TABLE 11

DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2024

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	307	32.5	324	33.1	631	32.8
Radiation	68	7.2	120	12.2	188	9.8
Chemotherapy	149	15.8	134	13.7	283	14.7
Immunotherapy	12	1.3	24	2.4	36	1.9
Interventional	35	3.7	11	1.1	46	2.4
Surgery & Radiotherapy	26	2.8	31	3.2	57	3.0
Surgery & Chemotherapy	83	8.8	119	12.1	202	10.5
Surgery & Hormone	1	0.1	0	0.0	1	0.1
Surgery & Immunotherapy	4	0.4	2	0.2	6	0.3
Surgery & Interventional	3	0.3	1	0.1	4	0.2
Radiotherapy & Chemotherapy	27	2.9	11	1.1	38	2.0
Radiotherapy & Immunotherapy	0	0.0	1	0.1	1	0.1
Chemotherapy & Hormone	1	0.1	0	0.0	1	0.1
Chemotherapy & Immunotherapy	22	2.3	30	3.1	52	2.7
Chemotherapy & Interventional	10	1.1	3	0.3	13	0.7
Surgery, Radiotherapy & Chemotherapy	15	1.6	15	1.5	30	1.6



TABLE 11 DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2024						
Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery, Chemotherapy & Immunotherapy	4	0.4	10	1.0	14	0.7
Surgery, Chemotherapy & Interventional	2	0.2	1	0.1	3	0.2
Radiotherapy, Chemotherapy & Immunotherapy	1	0.1	2	0.2	3	0.2
Surgery, Radiotherapy, Chemotherapy & Immunotherapy	0	0.0	1	0.1	1	0.1
Radiotherapy, Chemotherapy, Hormone & Immunotherapy	0	0.0	1	0.1	1	0.1
Counseling	174	18.4	139	14.2	313	16.3
Total	944	100.0	980	100.0	1924	100.0





Treatment unit	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Department of Medicine	370	39.2	319	32.6	689	35.8
Department of Surgery	445	47.1	319	32.6	764	39.7
Department of Ear, Nose and Throat	77	8.2	66	6.7	143	7.4
Department of Obstetrics and Gynecology	0	0.0	166	16.9	166	8.6
Department of Radiology	30	3.2	94	9.6	124	6.4
Department of Pediatrics	11	1.2	6	0.6	17	0.9
Department of Orthopedics	11	1.2	10	1.0	21	1.1
Total	944	100.0	980	100.0	1924	100.0

FIGURE 11: DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT UNIT AND GENDER: 2024







TABLE 13 DISTRIBUTION OF NEW CANCER PATIENTS BY STATUS : 2024						
Status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Military	257	27.2	35	3.6	292	15.2
Civilian	687	72.8	945	96.4	1632	84.8
Total	944	100.0	980	100.0	1924	100.0

TABLE 14 DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP STATUS AND GENDER : 2024						
Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	706	74.8	819	83.6	1525	79.3
Deaths	238	25.2	161	16.4	399	20.7
Total	944	100.0	980	100.0	1924	100.0

Survey: 15 May 2025

FIGURE 12: DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP STATUS: 2024



2024 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



TABLE 15 DISTRIBUTION OF NEW MILITARY PERSONNEL CANCER PATIENTS BY AGE GROUP AND GENDER : 2024

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
0 – 19	0	0.0	0	0.0	0	0.0
20 – 24	3	1.2	0	0.0	3	1.0
25 – 29	1	0.4	1	2.9	2	0.7
30 – 34	6	2.3	1	2.9	7	2.4
35 – 39	2	0.8	1	2.9	3	1.0
40 – 44	4	1.6	3	8.6	7	2.4
45 – 49	7	2.7	1	2.9	8	2.7
50 – 54	12	4.6	5	14.2	17	5.8
55 – 59	18	7.0	8	22.8	26	8.9
60 – 64	49	19.1	2	5.7	51	17.5
65 – 69	47	18.3	2	5.7	49	16.8
70 – 74	34	13.2	6	17.1	40	13.7
75 – 79	36	14.0	2	5.7	38	13.1
80 – 84	20	7.8	1	2.9	21	7.2
85 +	18	7.0	2	5.7	20	6.8
Total	257	100.0	35	100.0	292	100.0

Majority of cases

FIGURE 13: DISTRIBUTION OF NEW MILITARY PERSONNEL CANCER PATIENTS BY AGE GROUP AND GENDER: 2024







TABLE 16

DISTRIBUTION OF NEW CANCER PATIENTS BY RANK AND GENDER : 2024

Rank	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Major General – General	65	25.3	15	42.9	80	27.4
Major – Colonel	68	26.5	12	34.3	80	27.4
Sub Lieutenant – Captain	81	31.5	3	8.5	84	28.8
Sergeant Major 3 rd - Sergeant Major 1 st	33	12.8	4	11.4	37	12.7
Private 1 st class – Sergeant	6	2.3	1	2.9	7	2.4
Enlisted Soldier	4	1.6	0	0.0	4	1.3
Total	257	100.0	35	100.0	292	100.0

FIGURE 14: DISTRIBUTION OF NEW CANCER PATIENTS BY RANK AND GENDER: 2024



2024 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



TABLE 17 DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY AGE GROUP AND GENDER : 2024						
Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
0 – 4	5	33.3	3	37.5	8	34.8
5 – 9	3	20.0	2	25.0	5	21.7
10 – 14	6	40.0	1	12.5	7	30.4
15 - 19	1	6.7	2	25.0	3	13.0
Total	15	100.0	8	100.0	23	100.0

TABLE 18 DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY PRIMARY SITES : 2024					
Ordinal	Primary site	Male	Female	Total	
		Number	Number	Number	Percent
1	leukemia	4	4	8	34.8
2	Bone & articular cartilage	2	2	4	17.4
	Non-Hodgkin's lymphoma	3	1	4	17.4
3	Brain	2	1	3	13.0
4	Hodgkin's disease	2	0	2	8.7
5	Kidney, renal pelvis & ureter	1	0	1	4.3
	other endocrine glands	1	0	1	4.3
Total		15	8	23	100.0






TABLE 19 DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY TREATMENT MODALITIES AND GENDER : 2024

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	0	0.0	2	25.0	2	8.7
Radiation	1	6.7	0	0.0	1	4.3
Chemotherapy	5	33.3	6	75.0	11	47.8
Surgery & Radiotherapy	1	6.7	0	0.0	1	4.3
Surgery & Chemotherapy	5	33.3	0	0.0	5	21.7
Radiotherapy & Chemotherapy	1	6.7	0	0.0	1	4.3
Counseling	2	13.3	0	0.0	2	8.7
Total	15	100.0	8	100.0	23	100.0

TABLE 20 DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY METHOD OF DIAGNOSIS AND GENDER : 2024

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology or Cytology	6	40.0	3	37.5	9	39.1
Bone marrow	9	60.0	5	62.5	14	60.9
Total	15	100.0	8	100.0	23	100.0



2024 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



TABLE 21

DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19)
BY TYPE OF EXTENSION AND GENDER : 2024

Spreading/Metastasis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	13	86.7	8	100.0	21	91.3
Distant metastasis	2	13.3	0	0.0	2	8.7
Total	15	100.0	8	100.0	23	100.0

TABLE 22

DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19)
BY FOLLOW UP AND GENDER : 2024

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	13	86.7	7	87.5	20	87.0
Deaths	2	13.3	1	12.5	3	13.0
Total	15	100.0	8	100.0	23	100.0

Survey: 15 May 2025





TABLE 23		NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2024							
Site	Sex	Stage							
		I	II	III	IV	No stage	Un known	Total	
Bladder	Male	11	9	14	2	-	-	36	
	Female	4	2	3	2	-	-	11	
	Total	(N)	15	11	17	4	-	-	47
		(%)	31.9	23.4	36.2	8.5	-	-	100.0
Bone & articular cartilage	Male	1	5	0	1	-	-	7	
	Female	4	4	1	1	-	-	10	
	Total	(N)	5	9	1	2	-	-	17
		(%)	29.4	52.9	5.9	11.8	-	-	100.0
Brain	Male	-	-	-	0	13	-	13	
	Female	-	-	-	1	9	-	10	
	Total	(N)	-	-	-	1	22	-	23
		(%)	-	-	-	4.3	95.7	-	100.0
Breast	Male	0	0	1	0	-	-	1	
	Female	62	65	63	40	-	-	230	
	Total	(N)	62	65	64	40	-	-	231
		(%)	26.8	28.1	27.7	17.4	-	-	100.0
bronchus & lung	Male	16	6	23	75	-	0	120	
	Female	15	12	8	64	-	1	100	
	Total	(N)	31	18	31	139	-	1	220
		(%)	14.1	8.2	14.1	63.2	-	0.5	100.0
Cervix	Male	0	0	0	0	-	-	0	
	Female	15	19	22	6	-	-	62	
	Total	(N)	15	19	22	6	-	-	62
		(%)	24.2	30.6	35.5	9.7	-	-	100.0



TABLE 23 NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2024

Site	Sex		Stage						Total
			I	II	III	IV	No stage	Un known	
Colon & Rectum	Male		20	38	38	29	-	1	126
	Female		26	22	18	38	-	0	104
	Total	(N)	46	60	56	67	-	1	230
		(%)	20.0	26.1	24.3	29.1	-	0.4	100.0
Digestive organ	Male		9	12	18	20	-	-	59
	Female		5	9	13	9	-	-	36
	Total	(N)	14	21	31	29	-	-	95
		(%)	14.7	22.1	32.6	30.5	-	-	100.0
Eye	Male		-	-	-	1	-	-	1
	Female		-	-	-	0	-	-	0
	Total	(N)	-	-	-	1	-	-	1
		(%)	-	-	-	100.0	-	-	100.0
Malignant neoplasm of placenta	Male		0	-	0	-	-	-	0
	Female		1	-	1	-	-	-	2
	Total	(N)	1	-	1	-	-	-	2
		(%)	50.0	-	50.0	-	-	-	100.0
Malignant neoplasm of vulva			0	0	0	0	-	-	0
			1	1	1	1	-	-	4
	Total	(N)	1	1	1	1	-	-	4
		(%)	25.0	25.0	25.0	25.0	-	-	100.0
Hodgkin's disease	Male		-	1	3	0	-	-	4
	Female		-	0	1	1	-	-	2
	Total	(N)	-	1	4	1	-	-	6
		(%)	-	16.7	66.7	16.7	-	-	100.0



TABLE 23		NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2024							
Site	Sex	Stage							
		I	II	III	IV	No stage	Un known	Total	
Kidney, renal pelvis & ureter	Male	12	3	3	13	-	-	31	
	Female	3	0	2	4	-	-	9	
	Total	(N)	15	3	5	17	-	-	40
		(%)	37.5	7.5	12.5	42.5	-	-	100.0
Leukemia	Male	3	6	7	4	18	3	41	
	Female	8	6	5	1	11	8	39	
	Total	(N)	11	12	12	5	29	11	80
		(%)	13.8	15.0	15.0	6.3	36.3	13.8	100.0
Lip & Oral cavity	Male	4	15	20	31	-	-	70	
	Female	6	5	12	3	-	-	26	
	Total	(N)	10	20	32	34	-	-	96
		(%)	10.4	20.8	33.3	35.4	-	-	100.0
Liver & intrahepatic bile ducts	Male	8	29	21	31	-	-	89	
	Female	2	10	5	12	-	-	29	
	Total	(N)	10	39	26	43	-	-	118
		(%)	8.5	33.1	22.0	36.4	-	-	100.0
Malignant neoplasm of penis	Male	2	-	1	1	-	-	4	
	Female	0	-	0	0	-	-	0	
	Total	(N)	2	-	1	1	-	-	4
		(%)	50.0	-	25.0	25.0	-	-	100.0
Malignant neoplasm of testis	Male	1	1	1	-	-	-	3	
	Female	0	0	0	-	-	-	0	
	Total	(N)	1	1	1	-	-	-	3
		(%)	33.3	33.3	33.3	-	-	-	100.0



TABLE 23 NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2024


Site	Sex		Stage						Total
			I	II	III	IV	No stage	Un known	
Mesothelial & soft tissue	Male		1	1	5	2	-	-	9
	Female		1	1	2	2	-	-	6
	Total	(N)	2	2	7	4	-	-	15
		(%)	13.3	13.3	46.7	26.7	-	-	100.0
Non-Hodgkin's lymphoma	Male		6	17	12	27	-	2	64
	Female		2	9	5	11	-	2	29
	Total	(N)	8	26	17	38	-	4	93
		(%)	8.6	28.0	18.2	40.9	-	4.3	100.0
Endocrine gland	Male		1	-	0	2	-	-	3
	Female		0	-	1	0	-	-	1
	Total	(N)	1	-	1	2	-	-	4
		(%)	25.0	-	25.0	50.0	-	-	100.0
Ovary	Male		0	0	0	0	-	0	0
	Female		15	3	6	16	-	1	41
	Total	(N)	15	3	6	16	-	1	41
		(%)	36.7	7.3	14.6	39.0	-	2.4	100.0
Pancreas	Male		5	5	5	17	-	-	32
	Female		3	1	3	12	-	-	19
	Total	(N)	8	6	8	29	-	-	51
		(%)	15.7	11.8	15.7	56.9	-	-	100.0
Prostate gland	Male		52	27	24	35	-	5	143
	Female		0	0	0	0	-	0	0
	Total	(N)	52	27	24	35	-	5	143
		(%)	36.4	18.9	16.8	24.5	-	3.5	100.0



TABLE 23		NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2024							
Site	Sex		Stage						
			I	II	III	IV	No stage	Un known	Total
Respiratory & Intrathoracic organ	Male		6	4	5	9	-	-	24
	Female		1	1	1	3	-	-	6
	Total	(N)	7	5	6	12	-	-	30
		(%)	23.3	16.7	20.0	40.0	-	-	100.0
Skin	Male		16	9	2	2	-	-	29
	Female		18	5	0	2	-	-	25
	Total	(N)	34	14	2	4	-	-	54
		(%)	63.0	25.9	3.7	7.4	-	-	100.0
Thyroid gland	Male		12	9	5	5	-	-	31
	Female		74	12	16	11	-	-	113
	Total	(N)	86	21	21	16	-	-	144
		(%)	59.7	14.6	14.6	11.1	-	-	100.0
Uterus	Male		0	0	0	0	-	-	0
	Female		32	12	11	9	-	-	64
	Total	(N)	32	12	11	9	-	-	64
		(%)	50.0	18.8	17.2	14.0	-	-	100.0
Without specification of site	Male		-	-	1	3	-	-	4
	Female		-	-	0	2	-	-	2
	Total	(N)	-	-	1	19	-	-	6
		(%)	-	-	16.7	83.3	-	-	100.0
Total	Male		186	198	210	313	31	6	944
	Female		299	199	200	251	20	11	980
	Total	(N)	485	397	410	564	51	17	1924
		(%)	25.2	20.6	21.3	29.3	2.7	0.9	100.0



DESCRIPTION OF THE LEADING SITES OF CANCERS






1
BREAST
CANCER



TABLE 24

TREND OF BREAST CANCER IN PHRAMONGKUTKLAO HOSPITAL : 2013 - 2024

Years	Number of patients		Total
	Male	Female	
2013	1	285	286
2014	0	261	261
2015	2	197	199
2016	2	198	200
2017	5	166	171
2018	4	180	184
2019	3	206	209
2020	3	181	184
2021	2	210	212
2022	5	221	226
2023	2	187	189
2024	1	230	231






BREAST CANCER

TABLE 25 DISTRIBUTION OF BREAST CANCER PATIENTS BY AGE GROUP AND GENDER : 2024

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 24	0	0.0	0	0.0	0	0.0
25 – 29	0	0.0	2	0.9	2	0.9
30 – 34	0	0.0	4	1.7	4	1.7
35 – 39	0	0.0	9	3.9	9	3.9
40 – 44	0	0.0	18	7.8	18	7.8
45 – 49	0	0.0	23	10.0	23	10.0
50 – 54	0	0.0	32	13.9	32	13.9
55 – 59	0	0.0	36	15.8	36	15.6
60 – 64	0	0.0	32	13.9	32	13.9
65 – 69	0	0.0	33	14.3	33	14.3
70 – 74	0	0.0	13	5.7	13	5.6
75 – 79	1	100.0	15	6.5	16	6.8
80 – 84	0	0.0	7	3.0	7	3.0
85 +	0	0.0	6	2.6	6	2.6
Total	1	100.0	230	100.0	231	100.0

Majority of cases

FIGURE 21: DISTRIBUTION OF BREAST CANCER PATIENTS BY AGE GROUP AND GENDER: 2024







BREAST CANCER

TABLE 26 **DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY STAGE AND GENDER : 2024**

Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	0	0.0	62	27.0	62	26.9
Stage II	0	0.0	65	28.2	65	28.1
Stage III	1	100.0	63	27.4	64	27.7
Stage IV	0	0.0	40	17.4	40	17.3
Total	1	100.0	230	100.0	231	100.0

FIGURE 22: DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY STAGE AND GENDER: 2024





BREAST CANCER

TABLE 27

DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY METHOD OF DIAGNOSIS AND GENDER : 2024


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	0	0.0	2	0.9	2	0.9
Histopathology or Cytology	1	100.0	228	99.1	229	99.1
Total	1	100.0	230	100.0	231	100.0

TABLE 28

DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY EXTENSION AND GENDER : 2024

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	0	0.0	117	50.9	117	50.6
Regional lymph nodes	1	100.0	72	31.3	73	31.6
Distant metastasis	0	0.0	41	17.8	41	17.8
Total	1	100.0	230	100.0	231	100.0

FIGURE 23: DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY EXTENSION AND GENDER: 2024





30

HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT

2024

BREAST CANCER

TABLE 29

DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2024

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	0	0.0	42	18.4	42	18.2
Radiation	0	0.0	26	11.4	26	11.3
Chemotherapy	0	0.0	32	13.9	32	13.9
Immunotherapy	0	0.0	3	1.3	3	1.3
Surgery & Radiotherapy	0	0.0	7	3.0	7	3.0
Surgery & Chemotherapy	1	100.0	59	25.7	60	26.0
Surgery & Immunotherapy	0	0.0	1	0.4	1	0.4
Radiotherapy & Chemotherapy	0	0.0	4	1.7	4	1.7
Chemotherapy & Immunotherapy	0	0.0	12	5.2	12	5.2
Surgery, Radiotherapy & Chemotherapy	0	0.0	3	1.3	3	1.3
Surgery, Chemotherapy & Immunotherapy	0	0.0	8	3.5	8	3.5
Radiotherapy, Chemotherapy & Immunotherapy	0	0.0	1	0.4	1	0.4
Surgery, Radiotherapy, Chemotherapy & Immunotherapy	0	0.0	1	0.4	1	0.4
Surgery, Radiotherapy, Chemotherapy, Hormone & Immunotherapy	0	0.0	1	0.4	1	0.4
Counseling	0	0.0	30	13.0	30	13.0
Total	1	100.0	230	100.0	231	100.0



BREAST CANCER

TABLE 30

DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2024

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	1	100.0	213	92.6	214	92.6
Deaths	0	0.0	17	7.4	17	7.4
Total	1	100.0	230	100.0	231	100.0

Survey: 15 May 2025





2


COLON AND RECTUM CANCER



TABLE 31

TREND OF COLON AND RECTUM CANCER IN PHRAMONGKUTKLAO HOSPITAL : 2013 - 2024

Years	Number of patients		Total
	Male	Female	
2013	131	87	218
2014	130	87	217
2015	120	81	201
2016	140	88	228
2017	102	67	169
2018	104	56	160
2019	132	91	223
2020	107	72	179
2021	117	82	199
2022	140	95	235
2023	147	102	249
2024	126	104	230






COLON AND RECTUM CANCER

TABLE 32 DISTRIBUTION OF COLON AND RECTUM CANCER PATIENTS BY AGE GROUP AND GENDER : 2024

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 29	0	0.0	0	0.0	0	0.0
30 – 34	0	0.0	2	1.9	2	0.9
35 – 39	2	1.6	2	1.9	4	1.7
40 – 44	3	2.4	3	2.9	6	2.6
45 – 49	4	3.2	8	7.7	12	5.2
50 – 54	5	4.0	8	7.7	13	5.7
55 – 59	11	8.7	9	8.7	20	8.7
60 – 64	21	16.7	14	13.5	35	15.2
65 – 69	30	23.8	15	14.4	45	19.6
70 – 74	19	15.1	13	12.5	32	13.9
75 – 79	14	11.1	10	9.6	24	10.4
80 – 84	9	7.1	10	9.6	19	8.3
85 +	8	6.3	10	9.6	18	7.8
Total	126	100.0	104	100.0	230	100.0

Majority of cases

FIGURE 15: DISTRIBUTION OF COLON & RECTUM CANCER PATIENTS BY AGE GROUP AND GENDER: 2024







COLON AND RECTUM CANCER

TABLE 33 DISTRIBUTION OF NEW COLON AND RECTUM CANCER PATIENTS BY STAGE AND GENDER : 2024

Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	20	15.9	26	25.0	46	18.7
Stage II	38	30.2	22	21.2	60	25.2
Stage III	38	30.2	18	17.3	56	23.9
Stage IV	29	23.0	38	36.5	67	28.7
Unknown	1	0.8	0	0.0	1	3.5
Total	126	100.0	104	100.0	230	100.0

FIGURE 16: DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY STAGE AND GENDER: 2024





COLON AND RECTUM CANCER

TABLE 34

DISTRIBUTION OF NEW COLON AND RECTUM CANCER PATIENTS BY METHOD OF DIAGNOSIS AND GENDER : 2024


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology or Cytology	118	93.7	98	94.2	216	93.9
Endoscopy	8	6.3	6	5.8	14	6.1
Total	126	100.0	104	100.0	230	100.0

TABLE 35

DISTRIBUTION OF NEW COLON AND RECTUM CANCER PATIENTS BY EXTENSION AND GENDER : 2024

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	70	55.6	55	52.9	125	54.3
Regional lymph nodes	28	22.2	12	11.5	40	17.4
Distant metastasis	28	22.2	37	35.6	65	28.3
Total	126	100.0	104	100.0	230	100.0

FIGURE 17: DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY EXTENSION AND GENDER: 2024





COLON AND RECTUM CANCER

TABLE 36

DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2024

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	53	42.1	50	48.1	103	44.8
Radiation	2	1.6	1	1.0	3	1.3
Chemotherapy	14	11.1	8	7.7	22	9.6
Immunotherapy	0	0.0	1	1.0	1	0.4
Interventional	1	0.8	0	0.0	1	0.4
Surgery & Radiotherapy	1	0.8	2	1.9	3	1.3
Surgery & Chemotherapy	29	23.0	15	14.4	44	19.1
Surgery & Interventional	1	0.8	0	0.0	1	0.4
Radiotherapy & Chemotherapy	0	0.0	1	1.0	1	0.4
Chemotherapy & Immunotherapy	1	0.8	5	4.8	6	2.6
Surgery, Radiotherapy & Chemotherapy	3	2.4	0	0.0	3	1.3
Counseling	21	16.7	21	20.2	42	18.3
Total	126	100.0	104	100.0	230	100.0

TABLE 37

DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2024

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	108	85.7	75	72.1	183	79.6
Deaths	18	14.3	29	27.9	47	20.4
Total	126	100.0	104	100.0	230	100.0

Survey: 15 May 2025



3

BRONCHUS AND LUNG CANCER





TABLE 38

TREND OF BRONCHUS AND LUNG CANCER IN PHRAMONGKUTKLAO HOSPITAL : 2013 - 2024

Years	Number of patients		Total
	Male	Female	
2013	131	87	218
2014	130	87	217
2015	120	81	201
2016	140	88	228
2017	102	67	169
2018	104	56	160
2019	132	91	223
2020	107	72	179
2021	117	82	199
2022	111	97	208
2023	108	88	196
2024	120	100	220






BRONCHUS AND LUNG CANCER

TABLE 39 DISTRIBUTION OF BRONCHUS AND LUNG CANCER PATIENTS BY AGE GROUP AND GENDER : 2024						
Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 24	0	0.0	0	0.0	0	0.0
25 – 29	3	2.5	3	3.0	6	2.6
30 – 34	3	2.5	1	1.0	4	1.8
35 – 39	4	3.3	2	2.0	6	2.7
40 – 44	8	6.6	5	5.0	13	5.9
45 – 49	5	4.2	8	8.0	13	5.9
50 – 54	6	5.0	10	10.0	16	7.3
55 – 59	12	10.0	11	11.0	23	10.5
60 – 64	19	15.8	12	12.0	31	14.1
65 – 69	17	14.2	17	17.0	34	15.5
70 – 74	16	13.3	10	10.0	26	11.8
75 – 79	11	9.2	7	7.0	18	8.2
80 – 84	11	9.2	7	7.0	18	8.2
85 +	5	4.2	7	7.0	12	5.5
Total	120	100.0	100	100.0	220	100.0

Majority of cases

FIGURE 18: DISTRIBUTION OF BRONCHUS AND LUNG CANCER PATIENTS BY AGE GROUP AND GENDER: 2024





BRONCHUS AND LUNG CANCER

TABLE 41

DISTRIBUTION OF NEW BRONCHUS AND LUNG CANCER PATIENTS BY METHOD OF DIAGNOSIS AND GENDER : 2024


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology or Cytology	120	100.0	100	100.0	220	100.0
Total	120	100.0	100	100.0	220	100.0

TABLE 42

DISTRIBUTION OF NEW BRONCHUS AND LUNG CANCER PATIENTS BY EXTENSION AND GENDER : 2024

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	39	32.5	35	35.0	74	33.6
Regional lymph nodes	14	11.7	7	7.0	21	9.6
Distant metastasis	67	55.8	58	58.0	125	56.8
Total	120	100.0	100	100.0	220	100.0

FIGURE 20: DISTRIBUTION OF NEW BRONCHUS AND LUNG CANCER PATIENTS BY EXTENSION AND GENDER: 2024





BRONCHUS AND LUNG CANCER

TABLE 43 DISTRIBUTION OF NEW BRONCHUS AND LUNG CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2024

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	34	28.4	37	37.0	71	32.2
Radiation	8	6.8	4	4.0	12	5.4
Chemotherapy	18	15.0	11	11.0	29	13.1
Immunotherapy	3	2.5	4	4.0	7	3.2
Surgery & Radiotherapy	3	2.5	3	3.0	6	2.7
Surgery & Chemotherapy	4	3.3	6	6.0	10	4.5
Surgery & Hormone	1	0.8	0	0.0	1	0.5
Surgery & Immunotherapy	0	0.0	1	1.0	1	0.5
Radiotherapy & Chemotherapy	3	2.5	1	1.0	4	1.8
Radiotherapy & Immunotherapy	0	0.0	1	1.0	1	0.5
Chemotherapy & Hormone	1	0.8	0	0.0	1	0.5
Chemotherapy & Immunotherapy	3	2.5	0	0.0	3	1.4
Surgery, Radiotherapy & Chemotherapy	1	0.8	3	3.0	4	1.8
Surgery, Chemotherapy & Immunotherapy	1	0.8	0	0.0	1	0.5
Radiotherapy, Chemotherapy & Immunotherapy	1	0.8	1	1.0	2	0.9
Counseling	39	32.5	28	28.0	67	30.5
Total	120	100.0	100	100.0	220	100.0

TABLE 44 DISTRIBUTION OF NEW BRONCHUS AND LUNG CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2024

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	74	61.7	70	70.0	144	65.5
Deaths	46	38.3	30	30.0	76	34.5
Total	120	100.0	100	100.0	220	100.0

Survey: 15 May 2025



4

THYROID GLAND
CANCER





TABLE 45

DISTRIBUTION OF THYROID GLAND CANCER PATIENTS BY AGE GROUP AND GENDER : 2024

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 19	0	0.0	0	0.0	0	0.0
20 – 24	0	0.0	3	2.7	3	2.1
25 – 29	2	6.5	13	11.5	15	10.4
30 – 34	3	9.7	15	13.3	18	12.5
35 – 39	1	3.2	12	10.6	13	9.0
40 – 44	2	6.5	17	15.0	19	13.2
45 – 49	3	9.7	16	14.2	19	13.2
50 – 54	4	12.9	10	8.8	14	9.7
55 – 59	8	25.8	11	9.7	19	13.2
60 – 64	7	22.5	6	5.3	13	9.0
65 – 69	1	3.2	3	2.7	4	2.8
70 – 74	0	0.0	5	4.4	5	3.5
75 – 79	0	0.0	2	1.8	2	1.4
Total	31	100.0	113	100.0	144	100.0

Majority of cases

FIGURE 24: DISTRIBUTION OF THYROID GLAND CANCER PATIENTS BY AGE GROUP AND GENDER: 2024






THYROID GLAND CANCER

TABLE 46 DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY STAGE AND GENDER : 2024

Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	12	38.7	74	65.5	86	59.7
Stage II	9	29.1	12	10.6	21	14.6
Stage III	5	16.1	16	14.2	21	14.6
Stage IV	5	16.1	11	9.7	16	11.1
Total	31	100.0	113	100.0	144	100.0

FIGURE 25: DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY STAGE AND GENDER: 2024





THYROID GLAND CANCER

TABLE 47

DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY METHOD OF DIAGNOSIS AND GENDER : 2024


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	1	3.2	0	0.0	1	0.7
Histopathology or Cytology	30	96.8	113	100.0	143	99.3
Total	31	100.0	113	100.0	144	100.0

TABLE 48

DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY EXTENSION AND GENDER : 2024

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	23	74.2	97	85.8	120	83.3
Regional lymph nodes	3	9.7	6	5.3	9	6.3
Distant metastasis	5	16.1	10	8.9	15	10.4
Total	31	100.0	113	100.0	144	100.0

FIGURE 26: DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY EXTENSION AND GENDER: 2024





THYROID GLAND CANCER

TABLE 49

DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2024

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	8	25.8	27	23.9	35	24.3
Radiation	14	45.2	72	63.7	86	59.7
Chemotherapy	0	0.0	1	0.9	1	0.7
Surgery & Radiotherapy	6	19.4	10	8.8	16	11.1
Surgery & Chemotherapy	2	6.4	1	0.9	3	2.1
Radiotherapy & Chemotherapy	0	0.0	1	0.9	1	0.7
Counseling	1	3.2	1	0.9	2	1.4
Total	31	100.0	113	100.0	144	100.0

TABLE 50

DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2024

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	31	100.0	112	99.1	143	99.3
Deaths	0	0.0	1	0.9	1	0.7
Total	31	100.0	113	100.0	144	100.0

Survey: 15 May 2025





5

PROSTATE GLAND
CANCER





TABLE 51

DISTRIBUTION OF PROSTATE GLAND CANCER PATIENTS BY AGE GROUP AND GENDER : 2024

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 54	0	0.0	0	0.0	0	0.0
55 – 59	7	4.9	0	0.0	7	4.9
60 – 64	26	18.1	0	0.0	26	18.1
65 – 69	28	19.6	0	0.0	28	19.6
70 – 74	33	23.1	0	0.0	33	23.1
75 – 79	28	19.6	0	0.0	28	19.6
80 – 84	14	9.8	0	0.0	14	9.8
85 +	7	4.9	0	0.0	7	4.9
Total	143	100.0	0	0.0	143	100.0

Majority of cases

FIGURE 27: DISTRIBUTION OF PROSTATE GLAND CANCER PATIENTS BY AGE GROUP AND GENDER: 2024







PROSTATE GLAND CANCER

TABLE 52 DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY STAGE AND GENDER : 2024

Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	52	36.4	0	0.0	52	36.4
Stage II	28	19.6	0	0.0	28	19.6
Stage III	25	17.5	0	0.0	25	17.5
Stage IV	38	26.6	0	0.0	38	26.6
Total	143	100.0	0	0.0	143	100.0

FIGURE 28: DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY STAGE AND GENDER: 2024





PROSTATE GLAND CANCER

TABLE 53

DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY METHOD OF DIAGNOSIS AND GENDER : 2024


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	1	0.7	0	0.0	1	0.7
Histopathology or Cytology	142	99.3	0	0.0	142	99.3
Total	143	100.0	0	0.0	143	100.0

TABLE 54

DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY EXTENSION AND GENDER : 2024

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	107	74.8	0	0.0	107	74.8
Regional lymph nodes	4	2.8	0	0.0	4	2.8
Distant metastasis	32	22.4	0	0.0	32	22.4
Total	143	100.0	0	0.0	143	100.0

FIGURE 29: DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY EXTENSION AND GENDER: 2024





PROSTATE GLAND CANCER

TABLE 55 DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2024

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	54	23.1	0	0.0	54	23.1
Radiation	35	37.7	0	0.0	35	37.7
Chemotherapy	5	24.5	0	0.0	5	24.5
Surgery & Radiotherapy	8	3.5	0	0.0	8	3.5
Surgery & Chemotherapy	5	5.6	0	0.0	5	5.6
Radiotherapy & Chemotherapy	2	3.5	0	0.0	2	3.5
Surgery, Radiotherapy & Chemotherapy	1	1.4	0	0.0	1	1.4
Counseling	33	0.7	0	0.0	33	0.7
Total	143	100.0	0	0.0	143	100.0

TABLE 56 DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2024

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	132	92.3	0	0.0	132	90.4
Deaths	11	7.7	0	0.0	11	7.5
Total	143	100.0	0	0.0	146	100.0

Survey: 15 May 2025





6

LIVER AND INTRAHEPATIC BILE DUCTS
CANCER





TABLE 57

DISTRIBUTION OF LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY AGE GROUP AND GENDER : 2024

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 24	0	0.0	0	0.0	0	0.0
25 – 29	0	0.0	1	3.4	1	0.8
30 – 34	2	2.2	0	0.0	2	1.7
35 – 39	2	2.2	0	0.0	2	1.7
40 – 44	1	1.1	1	3.4	2	1.7
45 – 49	7	7.9	1	3.4	8	6.8
50 – 54	10	11.2	0	0.0	10	8.5
55 – 59	8	9.0	4	13.8	12	10.2
60 – 64	15	16.9	4	13.8	19	16.1
65 – 69	16	18.0	4	13.8	20	16.9
70 – 74	11	12.4	3	10.3	14	11.9
75 – 79	6	6.7	4	13.8	10	8.5
80 – 84	5	5.7	5	17.4	10	8.5
85 +	6	6.7	2	6.9	8	6.7
Total	89	100.0	29	100.0	118	100.0

Majority of cases

FIGURE 30: DISTRIBUTION OF LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY AGE GROUP AND GENDER: 2024






LIVER AND INTRAHEPATIC BILE DUCTS CANCER

TABLE 58

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY STAGE AND GENDER : 2024

Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	8	9.0	2	6.9	10	8.5
Stage II	29	32.6	10	34.5	39	33.1
Stage III	21	23.6	5	17.2	26	22.0
Stage IV	31	34.8	12	41.4	43	36.4
Total	89	100.0	29	100.0	118	100.0

FIGURE 31: DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY STAGE AND GENDER: 2024





LIVER AND INTRAHEPATIC BILE DUCTS CANCER

TABLE 59

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY METHOD AND GENDER : 2024


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology or Cytology	47	52.8	21	72.4	68	57.6
Tumor marker	42	47.2	8	27.6	50	42.4
Total	89	100.0	29	100.0	118	100.0

TABLE 60

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY EXTENSION AND GENDER : 2024

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	65	73.0	19	65.5	84	71.2
Regional lymph nodes	0	0.0	2	6.9	2	1.7
Distant metastasis	24	27.0	8	27.6	32	27.1
Total	89	100.0	29	100.0	118	100.0

FIGURE 32: DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY EXTENSION AND GENDER: 2024





LIVER AND INTRAHEPATIC BILE DUCTS CANCER

TABLE 61

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2024

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	19	21.3	11	37.9	30	25.4
Chemotherapy	17	19.1	4	13.8	21	17.8
Interventional	26	29.2	6	20.7	32	27.1
Surgery & Chemotherapy	3	3.5	1	3.4	4	3.4
Chemotherapy & Interventional	10	11.2	2	6.9	12	10.2
Surgery, Chemotherapy & Interventional	2	2.2	0	0.0	2	1.7
Counseling	12	13.5	5	17.3	17	14.4
Total	89	100.0	29	100.0	118	100.0

TABLE 62

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2024

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	49	55.1	15	51.7	64	54.2
Deaths	40	44.9	14	48.3	54	45.8
Total	89	100.0	29	100.0	118	100.0

Survey: 15 May 2025





54

HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT

2024

● MALE ●

TABLE 63

DISTRIBUTION OF NEW CANCER IN MALE BY AGE - GROUP : 2024

ICD_10	Site	Age	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80	85	
			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Total	4	9	14	19	24	29	34	39	44	49	54	59	64	69	74	79	84		
C00-C14	Lip & Oral cavity	70	0	0	0	0	0	2	1	1	6	7	15	8	12	8	4	3	2	1	
C15-C17, C21-C24	Digestive organ	59	0	0	0	0	0	0	1	2	4	4	4	6	15	6	3	5	6	3	
C18-C20	Colon & Rectum	126	0	0	0	0	0	0	0	2	3	4	5	11	21	30	19	14	9	8	
C22	Liver & intrahepatic bile ducts	89	0	0	0	0	0	0	2	2	1	7	10	8	15	16	11	6	5	6	
C25	Pancreas	32	0	0	0	0	0	0	0	0	2	1	2	1	5	4	9	5	1	2	
C30-C33, C35-C39	Intrathoracic organs	24	0	0	0	0	0	1	1	0	0	3	5	1	5	1	3	2	2	0	
C34	bronchus & lung	120	0	1	0	0	0	0	2	1	3	4	8	15	22	18	19	12	5	10	
C40-C41	Bone & articular cartilage	7	0	0	2	0	1	0	1	0	0	0	0	0	0	1	0	1	0	1	
C43-C44	Skin	29	0	0	0	0	1	1	0	0	3	3	0	3	1	5	4	3	4	1	
C46-C49	Mesothelial & soft tissue	9	0	0	0	0	0	1	1	1	0	1	0	2	0	1	0	1	1	0	
C50	Breast	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
C60	Malignant neoplasm of penis	4	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	0	1	
C62-C63	Malignant neoplasm of testis	3	0	0	0	0	1	0	2	0	0	0	0	0	0	0	0	0	0	0	
C61	Prostate	143	0	0	0	0	0	0	0	0	0	0	0	7	26	28	33	28	14	7	
C64-C66	Kidney, renal pelvis & ureter	31	1	0	0	0	0	0	0	1	2	2	2	6	1	10	2	2	1	1	
C67	Bladder	36	0	0	0	0	0	0	0	0	0	2	2	1	5	7	5	7	3	4	
C69	Eye & Meninges	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	
C70-C72	Brain	13	0	0	2	0	1	1	0	0	0	1	1	1	1	4	0	1	0	0	
C73	Thyroid gland	31	0	0	0	0	0	2	3	1	2	3	4	8	7	1	0	0	0	0	
C74-C75	Other endocrine glands	3	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	
C76-C80	Without specification of site	4	0	0	0	0	1	0	0	0	0	2	1	0	0	0	0	0	0	0	
C81	Hodgkin's disease	4	1	1	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	
C82-C88	Non-Hodgkin's lymphoma	64	1	0	2	0	2	3	2	5	1	2	5	9	4	8	7	5	3	5	
C90-C95	Leukemia	41	1	2		1	1		3	1	2	3	6	2	3	5	5	3	1	2	
Total		944	5	4	6	1	10	11	19	17	29	51	70	90	143	156	124	99	57	52	

2024 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



● FEMALE ●

TABLE 64		DISTRIBUTION OF NEW CANCER IN FEMALE BY AGE - GROUP : 2024																			
ICD_10	Site	Age	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80	85	
			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Total	4	9	14	19	24	29	34	39	44	49	54	59	64	69	74	79	84		
C00-C14	Lip & Oral cavity	26	0	0	0	0	1	1	0	2	2	4	6	3	1	1	1	0	2	2	
C15-C17, C21-C24	Digestive organ	36	0	0	0	0	0	2	2	1	1	3	4	5	4	1	4	3	2	4	
C18-C20	Colon & Rectum	104	0	0	0	0	0	0	2	2	3	8	8	9	14	15	13	10	10	10	
C22	Liver & intrahepatic bile ducts	29	0	0	0	0	0	1	0	0	1	1	0	4	4	4	3	4	5	2	
C25	Pancreas	19	0	0	0	0	0	0	1	0	0	0	3	2	4	2	2	0	2	3	
C30-C33, C35-C39	Intrathoracic organs	6	0	0	0	0	0	1	0	0	0	1	2	0	2	0	0	0	0	0	
C34	Bronchus & lung	100	0	0	0	0	1	0	0	2	4	10	11	13	11	15	12	10	6	5	
C40-C41	Bone & articular cartilage	10	1	0	1	0	0	1	0	2	0	3	0	0	1	0	0	0	0	1	
C43-C44	Skin	25	0	0	0	0	0	0	0	0	0	2	0	0	4	3	3	6	4	3	
C46-C49	Mesothelial & soft tissue	6	0	0	0	0	0	1	1	0	0	0	1	0	1	1	0	1	0	0	
C50	Breast	230	0	0	0	0	0	2	4	9	18	23	32	36	32	33	13	15	7	6	
C51-C52	Malignant neoplasm of placenta	2	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	
C57-C58	Malignant neoplasm of vulva	4	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	0	1	
C53	Cervix	62	0	0	0	0	1	3	5	11	10	5	8	5	5	3	2	2	1	1	
C54-C55	Uterus	64	0	0	0	0	0	0	2	4	3	6	5	10	12	13	3	2	3	1	
C56	Ovary	41	0	0	0	0	0	0	1	2	7	6	8	7	6	0	2	1	1	0	
C64-C66	Kidney, renal pelvis & ureter	8	0	0	0	0	0	0	1	0	0	1	1	0	2	2	0	0	0	1	
C67	Bladder	12	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	5	1	3	
C70-C72	Brain	10	1	0	0	0	0	1	0	0	0	1	1	0	2	2	1	0	0	1	
C73	Thyroid gland	113	0	0	0	0	3	13	15	12	17	16	10	11	6	3	5	2	0	0	
C74-C75	Other endocrine glands	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	
C76-C80	Without specification of site	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	
C81	Hodgkin's disease	2	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	
C82-C88	Non-Hodgkin's lymphoma	29	0	0	0	1	0	0	0	1	2	3	3	6	4	3	2	3	1	0	
C90-C95	Leukemia	39	1	2	0	1	1	1	1	2	0	6	4	3	4	3	4	4	2		
Total		980	3	2	1	2	7	27	35	52	69	100	107	116	121	107	72	68	47	44	



TABLE 65		DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2024			
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C00-C14	Lip & Oral cavity		70	26	96
C003	8073/3	Squamous cell carcinoma, spindle cell	1	0	1
C009	8073/3	Squamous cell carcinoma, spindle cell	1	0	1
C01	8070/3	Squamous cell carcinoma, NOS	3	1	4
	8070/6	Squamous cell carcinoma, metastatic, NOS	2	0	2
C020	8073/3	Squamous cell carcinoma, spindle cell	2	0	2
	8070/3	Squamous cell carcinoma, NOS	4	1	5
C021	8070/3	Squamous cell carcinoma, NOS	0	3	3
C0211	8070/3	Squamous cell carcinoma, NOS	3	0	3
C0219	8073/3	Squamous cell carcinoma, spindle cell	1	0	1
C023	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C024	8070/3	Squamous cell carcinoma, NOS	1	1	2
C029	-	-	0	1	1
C031	8070/3	Squamous cell carcinoma, NOS	3	3	6
	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	1	2
	8073/3	Squamous cell carcinoma, spindle cell	0	1	1
C049	8070/3	Squamous cell carcinoma, NOS	1	0	1
C050	8010/3	Carcinoma, NOS	0	1	1
C07	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8010/3	Carcinoma, NOS	0	1	1
	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8046/6	Non-small cell carcinoma, metastatic	1	0	1
C080	8140/3	Adenocarcinoma, NOS	1	0	1
	-	-	1	0	1
	8010/3	Carcinoma, NOS	1	0	1
C089	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
	9591/3	Malignant lymphoma, non-Hodgkin, NOS	0	1	1
	8010/3	Carcinoma, NOS	1	0	1
C090	8430/3	Mucoepidermoid carcinoma	0	1	1
	8070/3	Squamous cell carcinoma, NOS	3	2	5
C099	-	-	2	0	2
C101	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	2	1	3
	8480/3	Mucoinous adenocarcinoma	1	0	1
C102	8070/3	Squamous cell carcinoma, NOS	1	0	1
C109	8070/3	Squamous cell carcinoma, NOS	2	0	2
C112	8070/3	Squamous cell carcinoma, NOS	1	0	1
C119	-	-	0	1	1
	8010/3	Carcinoma, NOS	1	0	1

2024 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



TABLE 65

DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2024

ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
	8010/6	Carcinoma, metastatic, NOS	2	0	2
	8070/3	Squamous cell carcinoma, NOS	2	0	2
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
	8071/6	Squamous cell carcinoma, keratinizing, metastatic, NOS	2	0	2
	8073/3	Squamous cell carcinoma, spindle cell	1	1	2
C130	8010/3	Carcinoma, NOS	1	0	1
C131	-	-	1	0	1
C132	8073/6	Squamous cell carcinoma, spindle cell, metastatic	1	0	1
C139	-	-	1	0	1
	8070/3	Squamous cell carcinoma, NOS	9	0	9
C140	8070/3	Squamous cell carcinoma, NOS	2	2	4
	8073/3	Squamous cell carcinoma, spindle cell	0	1	1
C148	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8900/3	Rhabdomyosarcoma, NOS	0	1	1
C15-C17, C21-C24	Digestive organ		59	36	95
C150	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	1	0	1
C151	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	3	0	3
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C153	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C154	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C155	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	2	0	2
C159	8041/6	Small cell carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	3	0	3
	8070/6	Squamous cell carcinoma, metastatic, NOS	2	1	3
	8073/3	Squamous cell carcinoma, spindle cell	2	0	2
C160	-	-	1	0	1
	8140/3	Adenocarcinoma, NOS	2	1	3
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
C161	8140/3	Adenocarcinoma, NOS	1	1	2
	8336/3	Hyalinizing trabecular adenoma	1	0	1
C162	-	-	0	1	1
	8140/3	Adenocarcinoma, NOS	2	1	3
	8140/6	Adenocarcinoma, metastatic, NOS	0	2	2
C163	8140/3	Adenocarcinoma, NOS	3	1	4



TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2024					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C164	8140/3	Adenocarcinoma, NOS	0	1	1
C169	8010/3	Carcinoma, NOS	0	1	1
	8010/6	Carcinoma, metastatic, NOS	0	2	2
	8140/3	Adenocarcinoma, NOS	2	3	5
	8140/6	Adenocarcinoma, metastatic, NOS	1	2	3
	8936/3	Gastrointestinal stromal sarcoma	0	1	1
C170	-	-	0	1	1
C179	9250/3	Giant cell tumor of bone, malignant	1	0	1
C210	8010/3	Carcinoma, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	0	3	3
	8480/3	Mucinous adenocarcinoma	1	0	1
C211	8010/3	Carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	1	1
C218	-	-	1	1	2
	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	7	0	7
C23	-	-	1	0	1
	8140/3	Adenocarcinoma, NOS	2	0	2
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8480/3	Mucinous adenocarcinoma	0	1	1
C240	8140/3	Adenocarcinoma, NOS	1	1	2
	8140/6	Adenocarcinoma, metastatic, NOS	2	1	3
	8160/3	Cholangiocarcinoma	0	1	1
C241	8140/3	Adenocarcinoma, NOS	5	4	9
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
C248	8070/3	Squamous cell carcinoma, NOS	1	0	1
C18-C20	Colon & Rectum		126	104	230
C180	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	0	3	3
	8140/6	Adenocarcinoma, metastatic, NOS	0	3	3
C181	8480/6	Pseudomyxoma peritonei	1	0	1
C182	-	-	1	1	2
	8140/3	Adenocarcinoma, NOS	5	3	8
	8140/6	Adenocarcinoma, metastatic, NOS	0	3	3
C183	8140/3	Adenocarcinoma, NOS	4	1	5
	8480/3	Mucinous adenocarcinoma	1	0	1
C184	8140/3	Adenocarcinoma, NOS	3	1	4
	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2



TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2024					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C185	8140/3	Adenocarcinoma, NOS	2	0	2
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
	8480/3	Mucinous adenocarcinoma	1	0	1
C186	-	-	0	1	1
	8140/3	Adenocarcinoma, NOS	2	4	6
	8140/6	Adenocarcinoma, metastatic, NOS	2	3	5
C187	-	-	2	2	4
	8140/3	Adenocarcinoma, NOS	35	25	60
	8140/6	Adenocarcinoma, metastatic, NOS	5	17	22
	8170/3	Hepatocellular carcinoma, NOS	0	1	1
	8480/6	Pseudomyxoma peritonei	1	0	1
	9064/3	Germinoma	0	1	1
C189	8140/3	Adenocarcinoma, NOS	5	1	6
	8140/6	Adenocarcinoma, metastatic, NOS	2	4	6
C19	-	-	0	1	1
	8140/3	Adenocarcinoma, NOS	2	5	7
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C20	-	-	5	2	7
	8010/3	Carcinoma, NOS	1	0	1
	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	32	16	48
	8140/6	Adenocarcinoma, metastatic, NOS	9	4	13
	8246/3	Neuroendocrine carcinoma, NOS	1	0	1
C22	Liver & intrahepatic bile ducts		89	29	118
C220	-	-	39	6	45
	8010/3	Carcinoma, NOS	1	0	1
	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	1	1	2
	8140/6	Adenocarcinoma, metastatic, NOS	1	2	3
	8170/3	Hepatocellular carcinoma, NOS	0	1	1
	8170/3	Hepatocellular carcinoma, NOS	32	10	42
	8170/6	Hepatocellular carcinoma, metastatic, NOS	3	1	4
C221	-	-	2	1	3
	8140/3	Adenocarcinoma, NOS	1	5	6
	8140/6	Adenocarcinoma, metastatic, NOS	4	1	5
	8160/3	Cholangiocarcinoma	2	0	2
	8160/6	Cholangiocarcinoma, metastatic	1	1	2
C229	-	-	1	0	1



TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2024					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C25	Pancreas		32	19	51
C250	-	-	2	3	5
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	6	2	8
	8140/6	Adenocarcinoma, metastatic, NOS	3	0	3
	8480/3	Mucinous adenocarcinoma	1	0	1
C251	8140/3	Adenocarcinoma, NOS	3	1	4
	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2
C252	-	-	0	1	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	0	1	1
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
	8246/6	Neuroendocrine carcinoma, metastatic, NOS	1	0	1
C253	8140/6	Adenocarcinoma, metastatic, NOS	1	2	3
C254	8246/3	Neuroendocrine carcinoma, NOS	1	0	1
C257	8140/3	Adenocarcinoma, NOS	0	1	1
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
C259	8010/6	Carcinoma, metastatic, NOS	1	1	2
	8140/3	Adenocarcinoma, NOS	3	2	5
	8140/6	Adenocarcinoma, metastatic, NOS	6	3	9
	8246/6	Neuroendocrine carcinoma, metastatic, NOS	1	0	1
C30-C33, C35-C39	Intrathoracic organs		24	6	30
C300	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8073/3	Squamous cell carcinoma, spindle cell	1	0	1
	8140/3	Adenocarcinoma, NOS	0	1	1
C301	8070/3	Squamous cell carcinoma, NOS	1	1	2
C310	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8910/3	Embryonal rhabdomyosarcoma, NOS	1	0	1
C320	8070/3	Squamous cell carcinoma, NOS	5	0	5
C321	-	-	1	0	1
	8070/3	Squamous cell carcinoma, NOS	4	0	4
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C323	8070/3	Squamous cell carcinoma, NOS	1	0	1
C37	-	-	1	0	1
	8580/3	Thymoma, malignant, NOS	0	1	1
	8581/3	Thymoma, type A, malignant	1	0	1
	8582/3	Thymoma, type AB, NOS	1	0	1
	8584/3	Thymoma, typeB2, malignant	1	0	1
	8585/3	Thymoma, typeB3, malignant	1	0	1
C381	8850/3	Liposarcoma, NOS	1	0	1
	9764/3	Immunoproliferative small intestinal disease	1	0	1
C382	-	-	0	1	1
C383	8772/3	Spindle cell melanoma	0	1	1
	9650/3	Hodgkin lymphoma, NOS	1	0	1



TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2024					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C34	Bronchus & lung		120	100	220
C340	8010/3	Carcinoma, NOS	1	0	1
	8046/3	Non-small cell carcinoma	1	0	1
	8046/6	Non-small cell carcinoma, metastatic	1	2	3
	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	4	3	7
	8140/6	Adenocarcinoma, metastatic, NOS	6	3	9
	8312/6	Renal cell carcinoma, metastatic, NOS	1	0	1
C341	8010/3	Carcinoma, NOS	1	0	1
	8010/6	Carcinoma, metastatic, NOS	0	2	2
	8046/3	Non-small cell carcinoma	4	2	6
	8046/6	Non-small cell carcinoma, metastatic	1	1	2
	8140/3	Adenocarcinoma, NOS	6	7	13
	8140/6	Adenocarcinoma, metastatic, NOS	4	3	7
C342	8010/3	Carcinoma, NOS	1	0	1
	8046/3	Non-small cell carcinoma	1	0	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	1	1	2
	8140/6	Adenocarcinoma, metastatic, NOS	2	1	3
C343	8010/3	Carcinoma, NOS	0	2	2
	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8046/3	Non-small cell carcinoma	0	1	1
	8046/6	Non-small cell carcinoma, metastatic	1	0	1
	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	2	1	3
	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2
	8480/6	Pseudomyxoma peritonei	0	1	1
C349	-	-	1	1	2
	8010/3	Carcinoma, NOS	3	3	6
	8010/6	Carcinoma, metastatic, NOS	12	7	19
	8041/6	Small cell carcinoma, NOS	0	1	1
	8046/3	Non-small cell carcinoma	12	3	15
	8046/6	Non-small cell carcinoma, metastatic	12	9	21
	8140/3	Adenocarcinoma, NOS	12	18	30
	8140/6	Adenocarcinoma, metastatic, NOS	25	24	49
	8246/3	Neuroendocrine carcinoma, NOS	0	2	2
	8480/3	Mucinous adenocarcinoma	1	0	1



TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2024					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C40-C41	Bone & articular cartilage		7	10	17
C401	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8830/3	Malignant fibrous histiocytoma	1	0	1
	9220/3	Chondrosarcoma, NOS	0	2	2
C402	8801/3	Spindle cell sarcoma	1	1	2
	8802/3	Giant cell sarcoma	0	1	1
	9180/3	Osteosarcoma, NOS	3	0	3
	9180/6	Osteosarcoma, metastatic, NOS	1	0	1
	9250/3	Giant cell tumor of bone, malignant	0	1	1
	9260/3	Ewing sarcoma	0	2	2
C413	8801/6	Spindle cell sarcoma, metastatic	0	1	1
C414	9220/3	Chondrosarcoma, NOS	0	1	1
C419	9221/3	Juxtacortical chondrosarcoma	0	1	1
C43-C44	Skin		29	25	54
C433	8720/3	Malignant melanoma, NOS	1	0	1
C436	8720/3	Malignant melanoma, NOS	0	1	1
C437	-	-	0	1	1
	8720/3	Malignant melanoma, NOS	1	0	1
	8720/6	Malignant melanoma, metastatic, NOS	1	0	1
	8770/3	Mixed epithelioid and spindle cell melanoma	0	1	1
C439	8090/3	Basal cell carcinoma, NOS	0	1	1
	8090/6	Basal cell carcinoma, metastatic, NOS	0	1	1
	8720/3	Malignant melanoma, NOS	1	1	2
	8774/3	Spindle cell melanoma, type B	0	1	1
C440	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
	8090/3	Basal cell carcinoma, NOS	0	1	1
C441	8090/3	Basal cell carcinoma, NOS	1	0	1
C443	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8090/3	Basal cell carcinoma, NOS	7	9	16
C444	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8090/3	Basal cell carcinoma, NOS	2	0	2
	8832/3	Dermatofibrosarcoma, NOS	1	0	1
C445	8090/3	Basal cell carcinoma, NOS	0	1	1
	8832/3	Dermatofibrosarcoma, NOS	1	0	1
C447	8090/3	Basal cell carcinoma, NOS	1	0	1
C449	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	2	1	3
	8073/3	Squamous cell carcinoma, spindle cell	0	1	1
	8090/3	Basal cell carcinoma, NOS	6	5	11

2024 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



63

TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2024					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C46-C49	Mesothelial & soft tissue		9	6	15
C460	9140/3	Kaposi sarcoma	1	0	1
C480	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8811/3	Fibromyxosarcoma	0	1	1
	8850/3	Liposarcoma, NOS	0	1	1
C491	8890/3	Leiomyosarcoma, NOS	1	0	1
	9040/3	Synovial sarcoma, NOS	0	1	1
C492	8801/3	Spindle cell sarcoma	1	0	1
	8852/3	Myxoid liposarcoma	0	1	1
C494	-	-	3	0	3
	8801/3	Spindle cell sarcoma	1	0	1
C495	8801/6	Spindle cell sarcoma, metastatic	0	1	1
C496	8770/3	Mixed epithelioid and spindle cell melanoma	1	0	1
C499	8770/6	Mixed epithelioid and spindle cell melanoma, metastatic	1	0	1
C50	Breast		1	230	231
C500	8010/3	Carcinoma, NOS	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	0	9	9
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	1	1
	9020/3	Phyllodes tumor, malignant	0	1	1
C501	8500/3	Infiltrating duct carcinoma, NOS	0	3	3
C502	8500/3	Infiltrating duct carcinoma, NOS	0	6	6
C503	-	-	0	1	1
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	0	4	4
C504	8500/3	Infiltrating duct carcinoma, NOS	0	1	1
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	1	1
C505	8500/3	Infiltrating duct carcinoma, NOS	0	1	1
C509	-	-	0	3	3
	8010/3	Carcinoma, NOS	0	2	2
	8010/6	Carcinoma, metastatic, NOS	0	4	4
	8140/3	Adenocarcinoma, NOS	0	2	2
	8140/6	Adenocarcinoma, metastatic, NOS	0	4	4
	8200/3	Adenoid cystic carcinoma	0	1	1
	8341/3	Papillary microcarcinoma	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	1	158	159
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	25	25



TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2024					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C51-C52, C57-C58	Malignant neoplasms of female genital organs		0	6	6
C519	8070/3	Squamous cell carcinoma, NOS	-	1	1
	8542/3	Paget disease, extramammary	-	1	1
C52	8070/3	Squamous cell carcinoma, NOS	-	1	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	-	1	1
C570	8441/3	Serous cystadenocarcinoma, NOS	-	1	1
C58	-	-	-	1	1
C53	Cervix		0	62	62
C530	8070/6	Squamous cell carcinoma, metastatic, NOS	-	1	1
	8140/3	Adenocarcinoma, NOS	-	11	11
	8246/6	Neuroendocrine carcinoma, metastatic, NOS	-	1	1
C531	8010/3	Carcinoma, NOS	-	1	1
	8070/3	Squamous cell carcinoma, NOS	-	31	31
	8070/6	Squamous cell carcinoma, metastatic, NOS	-	3	3
	8073/3	Squamous cell carcinoma, spindle cell	-	6	6
	8073/6	Squamous cell carcinoma, spindle cell, metastatic	-	1	1
	8140/3	Adenocarcinoma, NOS	-	2	2
	8246/3	Neuroendocrine carcinoma, NOS	-	1	1
C539	8010/3	Carcinoma, NOS	-	1	1
	8070/3	Squamous cell carcinoma, NOS	-	2	2
	8140/3	Adenocarcinoma, NOS	-	1	1
C54-C55	Uterus		0	64	64
C541	-	-	-	1	1
	8010/3	Carcinoma, NOS	-	27	27
	8010/6	Carcinoma, metastatic, NOS	-	3	3
	8046/6	Non-small cell carcinoma, metastatic	-	1	1
	8130/3	Papillary transitional cell carcinoma	-	1	1
	8140/3	Adenocarcinoma, NOS	-	10	10
	8140/6	Adenocarcinoma, metastatic, NOS	-	2	2
	8310/3	Clear cell adenocarcinoma, NOS	-	2	2
	8310/6	Clear cell adenocarcinoma, metastatic, NOS	-	1	1
	8380/3	Endometrioid adenocarcinoma, NOS	-	6	6
	8441/3	Serous cystadenocarcinoma, NOS	-	5	5
	8980/3	Carcinosarcoma, NOS	-	2	2
	9831/3	T-cell large granular lymphocytic leukemia	-	1	1
C549	8380/3	Endometrioid adenocarcinoma, NOS	-	1	1
C55	8931/3	Endometrial stromal sarcoma, low grade	-	1	1

2024 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



65

TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2024

ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C56	Ovary		0	41	41
C56	8010/3	Carcinoma, NOS	-	6	6
	8010/6	Carcinoma, metastatic, NOS	-	1	1
	8070/3	Squamous cell carcinoma, NOS	-	3	3
	8140/3	Adenocarcinoma, NOS	-	4	4
	8140/6	Adenocarcinoma, metastatic, NOS	-	4	4
	8310/3	Clear cell adenocarcinoma, NOS	-	10	10
	8310/6	Clear cell adenocarcinoma, metastatic, NOS	-	2	2
	8336/6	Hyalinizing trabecular adenoma, metastatic	-	1	1
	8441/3	Serous cystadenocarcinoma, NOS	-	2	2
	8441/6	Serous cystadenocarcinoma, metastatic, NOS	-	3	3
	8480/3	Mucinous adenocarcinoma	-	4	4
	9080/3	Teratoma, malignant, NOS	-	1	1
C60,C62-C63	Malignant neoplasms of male genital organs		7	0	7
C601	8070/3	Squamous cell carcinoma, NOS	1	-	1
C602	8070/3	Squamous cell carcinoma, NOS	1	-	1
C609	8070/3	Squamous cell carcinoma, NOS	2	-	2
C621	8010/3	Carcinoma, NOS	1	-	1
C629	9085/3	Mixed germ cell tumor	1	-	1
C637	9085/3	Mixed germ cell tumor	1	-	1
C61	Prostate		143	0	143
C61	-	-	1	-	1
	8010/6	Carcinoma, metastatic, NOS	1	-	1
	8140/3	Adenocarcinoma, NOS	110	-	110
	8140/6	Adenocarcinoma, metastatic, NOS	31	-	31
C64-C66	Kidney, renal pelvis & ureter		31	8	39
C64	-	-	1	0	1
	8010/3	Carcinoma, NOS	0	1	1
	8010/6	Carcinoma, metastatic, NOS	2	0	2
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
	8260/3	Papillary adenocarcinoma, NOS	1	0	1
	8310/3	Clear cell adenocarcinoma, NOS	7	0	7
	8310/6	Clear cell adenocarcinoma, metastatic, NOS	1	0	1
	8312/3	Renal cell carcinoma, NOS	10	3	13
	8312/6	Renal cell carcinoma, metastatic, NOS	6	1	7
C65	8130/3	Papillary transitional cell carcinoma	1	0	1
C66	-	-	0	1	1
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8120/3	Transitional cell carcinoma, NOS	0	1	1
	8130/6	Papillary transitional cell carcinoma, metastatic	1	0	1



TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2024					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C67	Bladder		36	12	48
C670	8010/3	Carcinoma, NOS	1	0	1
	8120/3	Transitional cell carcinoma, NOS	1	0	1
	8130/3	Papillary transitional cell carcinoma	5	1	6
	8130/6	Papillary transitional cell carcinoma, metastatic	2	1	3
C672	8130/3	Papillary transitional cell carcinoma	3	1	4
C673	8010/3	Carcinoma, NOS	1	0	1
	8130/3	Papillary transitional cell carcinoma	1	0	1
C674	8130/3	Papillary transitional cell carcinoma	5	1	6
C678	8010/3	Carcinoma, NOS	1	0	1
C679	-	-	0	1	1
	8010/3	Carcinoma, NOS	3	0	3
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8050/3	Papillary carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	0	2	2
	8130/3	Papillary transitional cell carcinoma	12	4	16
C69	Eye & Meninges		1	0	1
C696	8070/3	Squamous cell carcinoma, NOS	1	0	1
C70-C72	Brain		13	10	23
C700	9530/3	Meningioma, malignant	1	0	1
C715	-	-	1	0	1
C717	9380/3	Glioma, malignant	0	1	1
C719	-	-	0	1	1
	8380/3	Endometrioid adenocarcinoma, NOS	0	1	1
	8720/3	Malignant melanoma, NOS	0	1	1
	9064/3	Germinoma	0	1	1
	9380/3	Glioma, malignant	7	2	9
	9401/3	Astrocytoma, anaplastic	1	0	1
	9440/3	Glioblastoma, NOS	1	2	3
	9530/3	Meningioma, malignant	0	1	1
C720	8010/3	Carcinoma, NOS	1	0	1
	9380/3	Glioma, malignant	1	0	1
C73	Thyroid gland		31	113	144
C73	-	-	1	6	7
	8010/6	Carcinoma, metastatic, NOS	1	1	2
	8050/3	Papillary carcinoma, NOS	18	75	93
	8050/6	Papillary carcinoma, metastatic, NOS	0	6	6
	8260/3	Papillary adenocarcinoma, NOS	5	15	20
	8260/6	Papillary adenocarcinoma, metastatic, NOS	4	3	7
	8330/3	Follicular adenocarcinoma, NOS	2	4	6
	8341/3	Papillary microcarcinoma	0	3	3

2024 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2024					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C74-C75	Other endocrine glands		3	1	4
C741	8680/3	Paraganglioma, malignant	1	0	1
C749	8004/3	Malignant tumor, spindle cell type	1	0	1
	8010/3	Carcinoma, NOS	0	1	1
	9500/6	Neuroblastoma, NOS	1	0	1
C76-C80	Without specification of site		4	2	6
C763	8910/3	Embryonal rhabdomyosarcoma, NOS	1	0	1
C786	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C795	8801/6	Spindle cell sarcoma, metastatic	0	1	1
C800	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
C809	8480/6	Pseudomyxoma peritonei	1	0	1
C81	Hodgkin's disease		4	2	6
C81	9650/3	Hodgkin lymphoma, NOS	1	1	2
	9650/6	Hodgkin lymphoma, metastatic, NOS	0	1	1
C810	9860/3	Myeloid leukemia, NOS	1	0	1
C819	9650/3	Hodgkin lymphoma, NOS	2	0	2
C82-C88	Non-Hodgkin's lymphoma		64	29	93
C82	9695/3	Follicular lymphoma, grade 1	0	1	1
C820	9695/3	Follicular lymphoma, grade 1	0	1	1
C824	9691/3	Follicular lymphoma, grade 2	1	0	1
	9698/3	Follicular lymphoma, grade 3	1	0	1
C829	9691/3	Follicular lymphoma, grade 2	1	0	1
	9695/3	Follicular lymphoma, grade 1	2	0	2
C830	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	1	0	1
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	1	0	1
C833	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	4	2	6
	9596/6	Composite Hodgkin and non-Hodgkin lymphoma, metastatic	1	0	1
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	19	8	27
	9680/6	Malignant lymphoma, large B-cell, diffuse, metastatic, NOS	3	2	5
C835	9590/3	Malignant lymphoma, NOS	0	1	1
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	0	1	1
C837	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	1	0	1
C838	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	0	1	1
C84	9590/6	Malignant lymphoma, metastatic, NOS	0	1	1



HOSPITAL-BASED CANCER REGISTRY 2024

ANNUAL REPORT

ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C840	9700/3	Mycosis fungoides	1	0	1
C844	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	0	1	1
C851	-	-	1	0	1
	9591/6	Malignant lymphoma, non-Hodgkin, metastatic, NOS	1	0	1
	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	3	1	4
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	1	1	2
C859	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	1	0	1
	9590/3	Malignant lymphoma, NOS	1	0	1
	9591/3	Malignant lymphoma, non-Hodgkin, NOS	0	1	1
	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	11	5	16
	9596/6	Composite Hodgkin and non-Hodgkin lymphoma, metastatic	3	1	4
	9695/3	Follicular lymphoma, grade 1	1	0	1
C862	9702/3	Mature T-cell lymphoma, NOS	0	1	1
C884	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	1	0	1
	9699/3	Marginal zone B-cell lymphoma, NOS	3	0	3
	9699/6	Marginal zone B-cell lymphoma, metastatic, NOS	1	0	1
C90-C95	leukaemia		41	39	80
C900	9732/3	Multiple myeloma	11	21	32
	9732/6	Multiple myeloma, metastatic	1	0	1
C901	9733/6	Plasma cell leukemia, metastatic	1	0	1
C910	9835/3	Precursor cell lymphoblastic leukemia, NOS	5	5	10
C911	9823/3	B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma	3	1	4
	9863/3	Chronic myeloid leukemia, NOS	1	0	1
C914	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	1	0	1
C920	-	-	1	2	3
	9861/3	Acute myeloid leukemia, NOS	11	6	17
C921	9861/3	Acute myeloid leukemia, NOS	1	0	1
	9863/3	Chronic myeloid leukemia, NOS	2	2	4
C924	9866/3	Acute promyelocytic leukemia, t(15;17)(q22;q11-12)	1	0	1
C946	9835/3	Precursor cell lymphoblastic leukemia, NOS	0	1	1
C950	9861/3	Acute myeloid leukemia, NOS	2	1	3
Total			944	980	1924



NEW CANCER PATIENTS 2020-2024

TABLE 66 NUMBER OF NEW CANCER PATIENTS : 2020 – 2024						
Years	New cancer case	Case	Male		Female	
	Number	Percent	Number	Percent	Number	Percent
2563 (2020)	1,608	18.73	800	18.83	808	18.63
2564 (2021)	1,526	17.78	771	18.15	755	17.41
2565 (2022)	1,702	19.83	822	19.35	880	20.30
2566 (2023)	1,825	21.26	912	21.46	913	21.06
2567 (2024)	1,924	22.41	944	22.22	980	22.60
Total	8,585	100.00	4,249	100.00	4,336	100.00

TABLE 67 DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP AND GENDER: 2020-2024						
Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	2,374	55.8	3,072	70.9	5,446	63.4
Deaths	1,879	44.2	1,260	29.1	3,139	36.6
Total	4,253	100.0	4,332	100.0	8,585	100.0

Survey: 15 May 2025





HOSPITAL-BASED CANCER REGISTRY **2024**

ANNUAL REPORT

TABLE 68 THE LEADING PRIMARY SITES OF NEW CANCER BY GENDER: 2020-2024							
Ordinal	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
1	Colon & Rectum	640	15.0	454	10.5	1,094	12.7
2	Breast	13	0.3	1,029	23.8	1,042	12.1
3	Bronchus & lung	544	12.8	415	9.6	959	11.2
4	Thyroid gland	124	2.9	489	11.3	613	7.1
5	Prostate gland	584	13.7	0	0.0	584	6.8
6	Liver & intrahepatic bile ducts	432	10.2	136	3.1	568	6.6
7	Non-Hodgkin's lymphoma	224	5.3	185	4.3	409	4.8
8	Cervix	0	0.0	247	5.7	247	2.9
	Leukemia	144	3.4	103	2.4	247	2.9
9	Corpus uteri	0	0.0	236	5.4	236	2.7
10	Skin	112	2.6	109	2.5	221	2.6

Survey: 15 May 2025

TABLE 69 THE LEADING PRIMARY SITES OF NEW CANCER BY FOLLOW UP AND GENDER: 2020-2024						
Ordinal	Primary site	Alive		Deaths		Total
		Male	Female	Male	Female	
1	Colon & Rectum	401	290	239	164	1,094
2	Breast	11	883	2	146	1,042
3	Bronchus & lung	186	197	358	218	959
4	Thyroid gland	109	464	15	25	613
5	Prostate gland	490	0	94	0	584
6	Liver & intrahepatic bile ducts	148	43	284	93	568
7	Non-Hodgkin's lymphoma	143	124	81	61	409
8	Cervix	0	186	0	61	247
	Leukemia	62	59	82	44	247
9	Corpus uteri	0	186	0	50	236
10	Skin	88	88	24	21	221

Survey: 15 May 2025



Ordinal	Primary site	Male	Female
1	Colon and Rectum	20.98	21.36
2	Breast	33.75	29.60
3	Bronchus and lung	9.71	14.78
4	Thyroid gland	23.50	29.64
5	Prostate gland	25.17	-
6	Liver and intrahepatic bile ducts	9.49	7.29

Survey: 15 May 2025

FIGURE 32: THE 60 MONTHS SERVIVAL RATE (TOP 6) IN 2020 – 2024






FIGURE 33: THE 60 MONTHS SURVIVAL RATE (TOP 6) BY MALE IN 2020 – 2024








FIGURE 34: THE 60 MONTHS SURVIVAL RATE (TOP 6) BY FEMALE IN 2020–2024



Phramongkutklo Hospital 315 Ratchawithi Rd, Bangkok 10400 Thailand.





PHRAMONGKUTKLAO HOSPITAL

EXCELLENT CENTER
OF CANCER CARE

2024

Oncology Unit and Epidemiology Unit,
Phramongkutklo Hospital.

315 Ratchawithi Road, Bangkok 10400, Thailand.

Tel. : + 66 2763 3925, + 66 2763 3047

Email : ceupmk@hotmail.com

Website : <http://ceu.pmk.ac.th>